Meeting the 2030 Target on Reducing the Global Burden of AMR: Pathways for Strengthening and Leveraging Surveillance in Developing Countries
By Prateek Sharma and Viviana Munoz Tellez
Antimicrobial Resistance (AMR) poses a major and growing threat to global health, yet low- and middle-income countries (LMICs) face significant challenges in implementing AMR surveillance –collection and analysis of data on AMR. Global AMR targets, including the United Nations’ goal of reducing AMR-associated deaths by 10 percent by 2030 and achieving diagnostic capacity in 80 percent of countries, rely on surveillance data that are often incomplete, hospital-centered, and unrepresentative of community infections in LMICs. While the Global Antimicrobial Resistance and Use Surveillance System (GLASS) of the World Health Organization (WHO) provides a standardized framework, in LMICs limited access to diagnostics, high laboratory costs, and reliance on data from specialized hospitals constrain participation and data comparability. Modeling studies have helped quantify the global burden of AMR, yet their reliance on sparse LMIC data underscores the need for improved primary surveillance. Achieving the United Nations’ 2030 target—where 80 per cent of countries can test resistance in all GLASS pathogens—will require substantial investment, technical support, and sustained political commitment. Embedding AMR surveillance within health systems and strengthening pandemic prevention and preparedness can help unlock external funding for eligible LMICs through the Pandemic Fund and the Global Fund.
Statement Delivered by the South Centre to the 79th World Health Assembly (WHA79)
Agenda Item 12.5 Primary Healthcare Agenda Item 12.8 Report of the Expert Advisory Group on the WHO Global Code of Practice on the International Recruitment of Health Personnel
Primary healthcare (PHC) is the backbone of Universal Health Coverage (UHC), health system resilience and the right to health. It is our first line of defense in emergencies and pandemics. Bold investment in PHC is overdue. Water, sanitation, and hygiene (WASH), the health workforce, integrated services and Antimicrobial Resistance (AMR) response cannot wait.
Statement by the South Centre on the Open-ended Intergovernmental Working Group on the WHO Pandemic Agreement
Geneva, 18 May 2026
The South Centre welcomes the one-year extension to finalise the Pathogen Access and Benefit-Sharing (PABS) Annex.
Developing countries showed remarkable unity and put forward concrete proposals. Had these been the basis of work, negotiations could have concluded sooner. Now all Parties must rise to the moment and deliver an Annex that meaningfully advances equity in pandemic prevention, preparedness and response.
No Country Can Cruise Past Collective Responsibility: The Hantavirus Outbreak
By Dr. Viviana Munoz Tellez
The hantavirus outbreak aboard the MV Hondius is a vivid reminder of why global health cooperation matters. It is one of many simultaneous outbreaks WHO is responding to, at a time the broader architecture of global health is under growing strain. The WHO faces deep funding shortfalls as some governments retreat from multilateralism. Despite International Health Regulations strengthened in response to COVID-19 and a newly adopted Pandemic Agreement, the system for pathogen access and benefit sharing that it must contain remains unfinished. Every country’s health security depends on global collaboration and solidarity.
Three Decades of Global Engagement: The South Centre’s Contribution to Intellectual Property and Development
By Nirmalya Syam
South Centre 30th Anniversary Series No. 2, 30 April 2026
This paper is part of a series of publications made in commemoration of the 30th anniversary of the South Centre, an intergovernmental organization established in 1995 to advance the interests of developing countries in global governance. Tracing its origins to the 1990 South Commission, it examines the Centre’s pivotal role in shaping intellectual property (IP) policies to promote equitable development. Through rigorous research, advocacy, and technical assistance, the South Centre has supported negotiations at the World Intellectual Property Organization (WIPO) and World Trade Organization (WTO), influencing milestones like the 2007 WIPO Development Agenda and extensions of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) transition periods for least developed countries.
Key contributions include promoting TRIPS flexibilities for public health, biodiversity, and technology transfer, with seminal publications on compulsory licensing, patent examination, and traditional knowledge protection. During the COVID-19 pandemic, the Centre advocated for IP waivers to enhance access to vaccines and therapeutics. Impacts include empowering Global South nations to implement development-oriented IP strategies and reform patent laws. Looking ahead, the paper addresses challenges from digital transformation, artificial intelligence (AI), and data governance, calling for strengthened South-South cooperation and proactive advocacy to ensure inclusive IP frameworks. The South Centre remains essential for fostering sustainable development and reducing global inequalities.
UK–India CETA: Patents and International Intellectual Property Governance
By Pratyush Nath Upreti & Virender Chandel
This policy brief locates the United Kingdom-India Comprehensive and Economic Trade Agreement’s (CETA) intellectual property rights (IPRs) rules in the midst of trade-offs. It succinctly provides an overview of the IPR Chapter, analyses the specific provisions on patents and contextualises IP in the broader context of international IP governance. The analysis of the IPR Chapter shows the parties’ objective to establish meaningful commitments on intellectual property protection and enforcement while preserving regulatory flexibility on development-centric and public health priorities. All in all, the IPR Chapter reflects a compromise between a country with an established, strong IP regime and a country seeking greater policy space and advancing IP norms in areas such as traditional knowledge. As India continues integrating into the global trade architecture through bilateral agreements, the CETA IPR Chapter will serve as a critical test case for whether strategic policy space can be meaningfully preserved within contemporary trade frameworks.
Towards an Operative Pathogen ABS System: Implementing the Equal Footing Requirement of Article 12 of the WHO Pandemic Agreement
By Viviana Munoz Tellez, Nirmalya Syam
Multilateral negotiations on the Pathogen Access and Benefit-Sharing (PABS) system remain deadlocked. As required by Article 12 of the World Health Organization (WHO) Pandemic Agreement, the annex operationalizing the PABS system must place on equal footing the rapid and timely sharing of PABS Materials and Sequence Information with the rapid, timely, fair and equitable sharing of benefits that arise from their sharing and utilization. The Annex cannot impose binding sharing obligations on State Parties while making it optional for users of PABS Materials to opt in to the PABS system voluntarily, without legally binding obligations on benefit sharing arising from the utilization of PABS Materials and Sequence Information. The Annex also cannot create a hybrid system providing alternative routes for access, either “open” or “restricted”. This would be inconsistent with Article 12 of the Pandemic Agreement and with the obligations of parties under the Convention on Biological Diversity and its Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization. The Annex must include a standardized contractual framework binding all actors in the PABS chain, a minimum manufacturer participation threshold before country obligations become active, and ensure benefit-sharing is not confined to pandemic emergencies.
Access to Medicines and Intellectual Property: taking advantage of TRIPS flexibilities for post-COVID-19 resilience in Africa
By Ismaelline Eba Nguema
The call by India and South Africa for the provisional lifting of patents on pharmaceutical products has had the merit of putting the issue of access to medicines and public health back on the agenda. However, the difficulty of reconciling access to medicines and intellectual property has many factors which cannot be reduced solely to the commitments of WTO member states. A more in-depth analysis reveals the intrinsic limitations of some of its members. These include the weakness of the legislative and regulatory framework in some countries, such as those on the African continent. Consequently, the aim of this article is to demonstrate that effective use of the flexibilities in the TRIPS Agreement is only possible if African countries equip themselves with an appropriate legal framework, in addition to the judicial institutions that are supposed to guarantee the effectiveness of the standards adopted. The methodology used consisted of an exegesis of various documents, including articles, working documents of the TRIPS Council, declarations and resolutions of various bodies, as well as the national case law of certain WTO members, etc. This method led us to conclude that the compatibility between access to medicines and intellectual property is caught between human rights and economic interests. However, for the TRIPS flexibilities to be fully utilized by African countries, they would benefit from reforming their legal frameworks to take advantage of the flexibilities in the TRIPS Agreement.
Addressing Barriers to Accessing Monoclonal Antibodies (mAbs) in Developing Countries: Challenges and Potential Solutions
By Nirmalya Syam
Monoclonal antibodies (mAbs) have revolutionized treatment in oncology, autoimmune disorders, and infectious diseases due to their high specificity and efficacy. However, access to mAbs in developing countries remains severely limited due to high costs, market concentration in high-income regions, regulatory hurdles, and intellectual property barriers. Despite the potential of biosimilars to enhance affordability, their availability remains restricted due to expensive development processes, patent thickets, and complex regulatory requirements. The dominance of multinational pharmaceutical companies in the market further restricts competition, delaying biosimilar approvals and preventing price reductions. Additionally, regulatory agencies in developing countries often lack the resources to expedite biosimilar approvals, further exacerbating delays in access.
Policy interventions such as improved regulatory harmonization, stricter patent examination guidelines, and expanded public investment in mAb production are necessary to address these barriers. The adoption of the revised 2022 WHO Similar Biotherapeutic Products (SBP) Guidelines could streamline biosimilar approval by reducing unnecessary comparative clinical trials. Moreover, technology transfer initiatives and market-shaping incentives, including compulsory licensing, could help lower costs and accelerate the availability of mAbs in underserved regions.
By implementing these strategies, developing countries can bridge the access gap, ensuring that lifesaving mAb therapies reach the patients who need them most. A coordinated global effort involving policymakers, regulators, and industry stakeholders is essential to establishing a sustainable and equitable mAb supply chain.
Global Activism to Make Patented Drugs More Accessible: An ITPC Case Study of Bedaquiline for Treatment of Tuberculosis
By Priti Patnaik
This report documents efforts by civil society organizations (CSOs) in various countries, including Brazil, Ukraine and Thailand, to make Bedaquiline more accessible by using the flexibilities provided in the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) – the safeguards in the intellectual property system that take into account public health needs. The case study was undertaken during 2023-2024.
Tuberculosis remains a major global health crisis, with drug-resistant forms requiring newer more effective treatments like Bedaquiline which offers shorter treatment times and fewer side effects than older regimens. The report offers an overview of global and country-specific efforts by CSOs to challenge patents held by Johnson & Johnson on the tuberculosis (TB) drug bedaquiline (BDQ) to improve patient access and affordability. CSOs primarily focused on opposing “evergreening” secondary patents that extend Johnson & Johnson’s monopoly beyond the original patent expiration, arguing that these patents lack inventive merit and artificially inflate prices. Successful actions, such as patent rejections in India and Thailand and Johnson & Johnson’s agreement not to enforce patents in 134 low- and middle-income countries (LMICs), are discussed alongside challenges, including judicial difficulties, insufficient political will, and the strategic importance of pursuing pre-grant patent oppositions.
South Centre and One Health Trust Information Note
March 2026
92 million deaths could be averted by 2050 with improved access to antibiotics and infection care. The time to act is now, and it requires both access and stewardship.
Together with One Health Trust, we highlight key recommendations to make it happen in a pointed brief.
* Available in 3 languages (English, Portuguese and Spanish)
